LEGEND: A randomised phase II study comparing lenalidomide plus rituximab, gemcitabine, and methylprednisolone (R-GEM-L) to rituximab, gemcitabine, methylprednisolone, and cisplatin (R-GEM-P) in second-line treatment of diffuse large B-cell lymphoma (DLBCL). Academic Article uri icon

  •  
  • Overview
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Gleeson, Mary
  • Chau, Ian
  • Peckitt, Clare
  • Patel, Bijal
  • Wotherspoon, Andrew
  • Attygalle, Ayoma
  • Du, Yong
  • Sharma, Bhupinder
  • Cunningham, David

publication date

  • May 20, 2014